Zimmer Biomet Receives FDA Breakthrough Designation for Iodine-Treated Hip Replacement System
Reuters
Oct 28, 2025
Zimmer Biomet Receives FDA Breakthrough Designation for Iodine-Treated Hip Replacement System
Zimmer Biomet Holdings Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its iodine-treated total hip replacement system, marking the first time a Zimmer Biomet product has received this designation. This system, which incorporates a controlled-release iodine surface treatment to help prevent periprosthetic joint infections in high-risk patients, was previously approved by Japan's Pharmaceutical and Medical Devices Agency (PMDA). The FDA Breakthrough Device Designation will expedite regulatory review in the U.S., allowing Zimmer Biomet to work closely with the agency to bring this innovative technology to patients. No other organizations were mentioned as recipients of this regulatory milestone.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zimmer Biomet Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DE08228) on October 28, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.